CTXR (Citius Pharmaceuticals) Inventories, Finished Goods: $15.71 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CTXR Citius Pharmaceuticals Inc CTXR
25 GF Score
Price $0.68
! 2 Warning Signs
View Full Analysis

What is Citius Pharmaceuticals Inventories, Finished Goods?

Citius Pharmaceuticals CTXR +6.28% 25 Inventories, Finished Goods is $15.71 Mil as of Mar. 2026. GuruFocus rates CTXR with a GF Score™ of 25/100. The stock has 2 warning signs investors should review.

Citius Pharmaceuticals's quarterly finished goods increased from Sep. 2025 ($10.58 Mil) to Dec. 2025 ($15.69 Mil) and increased from Dec. 2025 ($15.69 Mil) to Mar. 2026 ($15.71 Mil).

Citius Pharmaceuticals's annual finished goods increased from Sep. 2023 ($0.00 Mil) to Sep. 2024 ($6.14 Mil) and increased from Sep. 2024 ($6.14 Mil) to Sep. 2025 ($10.58 Mil).

Citius Pharmaceuticals Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Citius Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Pharmaceuticals Inventories, Finished Goods Chart

Citius Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 6.14 10.58

Citius Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 10.58 15.69 15.71
CTXR
25GF Score
Citius Pharmaceuticals Inc CTXR
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $15.71 Mil mean?
Citius Pharmaceuticals (CTXR) has a Inventories, Finished Goods of $15.71 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Citius Pharmaceuticals and its competitors.
Is Citius Pharmaceuticals' Inventories, Finished Goods too high?
Citius Pharmaceuticals' current Inventories, Finished Goods is $15.71 Mil. Overall, Citius Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Citius Pharmaceuticals' Inventories, Finished Goods compare to LEXX and HIND?
Citius Pharmaceuticals' Inventories, Finished Goods of $15.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Citius Pharmaceuticals and its competitors. Citius Pharmaceuticals's current Inventories, Finished Goods is $15.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Pharmaceuticals stock overvalued right now?
Citius Pharmaceuticals (CTXR) has a current Inventories, Finished Goods of $15.71 Mil. The current Inventories, Finished Goods is $15.71 Mil. Citius Pharmaceuticals' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Citius Pharmaceuticals (CTXR), the current Inventories, Finished Goods is $15.71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Pharmaceuticals Business Description

Address 11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
25GF Score

Get the complete analysis for CTXR

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.68
Price